Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
Status:
Active, not recruiting
Trial end date:
2021-11-15
Target enrollment:
Participant gender:
Summary
This is a phase 1b study of investigational drug selinexor in combination with doxorubicin in
patients with locally advanced or metastatic soft tissue sarcoma. The purpose of this study
is to determine how safe and tolerable the combination is, as well as the best dose of the
study drugs in this patient population.
Selinexor (also called KPT-330), works by trapping "tumor suppressor proteins" within the
cell and thus causing the cancer cells to die or stop growing.